Ay resistance and dynamic compliance in individual mouse strains (A) or combined for comparison (B). Data represent mean ?SEM, n = 8. Significance is TAK-385MedChemExpress Relugolix GDC-0084 site represented by *P < 0.05, **P < 0.01, ***P < 0.001 (Saline v OVA groups of the same strain), ##P < 0.01 (OVA v KSpn+OVA groups of the same strain), P < 0.01 (Wt v -/- between KSpn+OVA groups). doi:10.1371/journal.pone.0156402.gPLOS ONE | DOI:10.1371/journal.pone.0156402 June 16,11 /TLRs in Suppression of Allergic Airways DiseaseFig 7. Role of TLRs in AAD and KSpn-mediated suppression. In AAD TLR2 is involved in local IL-5 release from MLN T cells, the systemic release of IL-5 and IL-13 from splenocytes, and the induction of AHR (A). TLR4 is involved in eosinophil influx into the blood (partial) and airways, and the induction of AHR. The presence of either of these TLRs is required to control IL-13 production from MLNs. Many of these effects involve the TLR adaptor protein MyD88, which is required for blood eosinophilia, IL-13 release from MLN T cells and AHR. In KSpn-mediated suppression of AAD TLR2 is involved in the suppression of eosinophil infiltration into the airways and AHR (B). TLR4 is involved in the suppression of eosinophilia in the airways and blood, IL-5 and IL-13 release from splenocytes and AHR. Both TLRs are required for suppression of eosinophils in BALF due to the absence of TLR4, and blood due to the absence of TLR2. MyD88 is required for the suppression of airway and blood eosinophilia and AHR. doi:10.1371/journal.pone.0156402.gthe TLR2 ligand peptidoglycan that can up-regulate TLR2 expression [41]. TLR2 and TLR4 are expressed by DCs, macrophages, neutrophils, the airway epithelium and some subsets of Tregs, which implicates these cells in many processes that may be manipulated in TLR-directed therapies for AAD/asthma [2, 6, 42, 43].PLOS ONE | DOI:10.1371/journal.pone.0156402 June 16,12 /TLRs in Suppression of Allergic Airways DiseaseThis study shows that TLR2-/- mice with AAD had reduced IL-5 release from MLNs, IL-5 and IL-13 release from spleen and AHR compared to Wt. In KSpn-mediated suppression TLR2 was implicated in suppressing eosinophils in BALF (partial) and AHR. These outcomes demonstrate that the protective effects of KSpn are only partially dependent on TLR2. S. pneumoniae infection involves a TLR2 dependent crossing of the epithelial barrier to infect the lung [44]. Therefore in our study the protective effects of KSpn in AAD may not be as pronounced in TLR2-/- mice, because a lack of stimulation of the epithelium that is known to contribute to inflammatory responses in asthma [42]. The altered epithelial barrier in non-allergic TLR2-/mice may explain why these mice are protected against airway responsiveness compared to non-allergic Wt mice. TLR4-/- mice are protected against increases in BALF and blood (partial) eosinophils in AAD, highlighting that this receptor is required for eosinophil infiltration in AAD. The decreased levels of eosinophils are not due to reductions in IL-5 and IL-13. TLR4-/- mice have similar levels of airway resistance but increased dynamic compliance compared to Wt mice with AAD. In KSpn-mediated suppression TLR2 was implicated in suppressing blood and BALF eosinophils, splenic cytokine release and AHR. Local cytokine release was unaffected suggesting that the protective effects are systemic through as yet unknown mechanisms, potentially by inducing Tregs and modulating DCs in the periphery [18]. TLR2/4-/- mice with AAD had a trend.Ay resistance and dynamic compliance in individual mouse strains (A) or combined for comparison (B). Data represent mean ?SEM, n = 8. Significance is represented by *P < 0.05, **P < 0.01, ***P < 0.001 (Saline v OVA groups of the same strain), ##P < 0.01 (OVA v KSpn+OVA groups of the same strain), P < 0.01 (Wt v -/- between KSpn+OVA groups). doi:10.1371/journal.pone.0156402.gPLOS ONE | DOI:10.1371/journal.pone.0156402 June 16,11 /TLRs in Suppression of Allergic Airways DiseaseFig 7. Role of TLRs in AAD and KSpn-mediated suppression. In AAD TLR2 is involved in local IL-5 release from MLN T cells, the systemic release of IL-5 and IL-13 from splenocytes, and the induction of AHR (A). TLR4 is involved in eosinophil influx into the blood (partial) and airways, and the induction of AHR. The presence of either of these TLRs is required to control IL-13 production from MLNs. Many of these effects involve the TLR adaptor protein MyD88, which is required for blood eosinophilia, IL-13 release from MLN T cells and AHR. In KSpn-mediated suppression of AAD TLR2 is involved in the suppression of eosinophil infiltration into the airways and AHR (B). TLR4 is involved in the suppression of eosinophilia in the airways and blood, IL-5 and IL-13 release from splenocytes and AHR. Both TLRs are required for suppression of eosinophils in BALF due to the absence of TLR4, and blood due to the absence of TLR2. MyD88 is required for the suppression of airway and blood eosinophilia and AHR. doi:10.1371/journal.pone.0156402.gthe TLR2 ligand peptidoglycan that can up-regulate TLR2 expression [41]. TLR2 and TLR4 are expressed by DCs, macrophages, neutrophils, the airway epithelium and some subsets of Tregs, which implicates these cells in many processes that may be manipulated in TLR-directed therapies for AAD/asthma [2, 6, 42, 43].PLOS ONE | DOI:10.1371/journal.pone.0156402 June 16,12 /TLRs in Suppression of Allergic Airways DiseaseThis study shows that TLR2-/- mice with AAD had reduced IL-5 release from MLNs, IL-5 and IL-13 release from spleen and AHR compared to Wt. In KSpn-mediated suppression TLR2 was implicated in suppressing eosinophils in BALF (partial) and AHR. These outcomes demonstrate that the protective effects of KSpn are only partially dependent on TLR2. S. pneumoniae infection involves a TLR2 dependent crossing of the epithelial barrier to infect the lung [44]. Therefore in our study the protective effects of KSpn in AAD may not be as pronounced in TLR2-/- mice, because a lack of stimulation of the epithelium that is known to contribute to inflammatory responses in asthma [42]. The altered epithelial barrier in non-allergic TLR2-/mice may explain why these mice are protected against airway responsiveness compared to non-allergic Wt mice. TLR4-/- mice are protected against increases in BALF and blood (partial) eosinophils in AAD, highlighting that this receptor is required for eosinophil infiltration in AAD. The decreased levels of eosinophils are not due to reductions in IL-5 and IL-13. TLR4-/- mice have similar levels of airway resistance but increased dynamic compliance compared to Wt mice with AAD. In KSpn-mediated suppression TLR2 was implicated in suppressing blood and BALF eosinophils, splenic cytokine release and AHR. Local cytokine release was unaffected suggesting that the protective effects are systemic through as yet unknown mechanisms, potentially by inducing Tregs and modulating DCs in the periphery [18]. TLR2/4-/- mice with AAD had a trend.
